Impact of MDR-1 Gene on Acute Myeloblastic Leukaemia Outcomes
Author Information
Author(s): J.A. Holmes, R.R. West
Primary Institution: University of Wales College of Medicine
Hypothesis
Does P-glycoprotein expression influence the prognosis in acute myeloblastic leukaemia?
Conclusion
P-glycoprotein expression is associated with lower remission rates in acute myeloblastic leukaemia.
Supporting Evidence
- P-glycoprotein expression is linked to lower remission rates in AML.
- Meta-analysis included 12 studies with a total of 859 patients.
- Significant differences in remission rates were observed between MDR-positive and MDR-negative patients.
- Four studies reported significant results at the p<0.05 level.
- Two large studies reported no effect of P-170 expression on outcome.
Takeaway
Some leukaemia patients have a gene that makes it harder for their treatment to work, and this study looked at how that gene affects their chances of getting better.
Methodology
Meta-analysis of 12 studies examining the relationship between P-glycoprotein expression and treatment outcomes in AML.
Potential Biases
Potential publication bias may influence the perceived effectiveness of P-glycoprotein expression on outcomes.
Limitations
Variability in study methodologies, treatment regimens, and patient demographics may affect comparability.
Participant Demographics
Patients with acute myeloblastic leukaemia, demographics varied across studies.
Statistical Information
P-Value
0.68
Confidence Interval
0.60-0.70
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website